Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-01-05
2008-10-07
Desai, Rita (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S102000, C544S042000, C514S225500
Reexamination Certificate
active
07432257
ABSTRACT:
The invention is directed to delta opioid receptor modulators. More specifically, the invention relates to tricyclic δ-opioid modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described.
REFERENCES:
patent: 2368006 (1945-01-01), Cusic
patent: 2784185 (1957-03-01), Schuler
patent: 2901478 (1959-08-01), Schuler
patent: 3179665 (1965-04-01), Schmutz
patent: 3305547 (1967-02-01), Bickelhaupt et al.
patent: 3470188 (1969-09-01), Kaiser et al.
patent: 3557287 (1971-01-01), Berde et al.
patent: 3931232 (1976-01-01), Bender et al.
patent: 3987042 (1976-10-01), Gueremy et al.
patent: 4086350 (1978-04-01), Zirkle
patent: 4275209 (1981-06-01), Lassen et al.
patent: 4356184 (1982-10-01), Deason et al.
patent: 4666907 (1987-05-01), Fortin et al.
patent: 4777177 (1988-10-01), Traber et al.
patent: 5502049 (1996-03-01), Garret et al.
patent: 6004983 (1999-12-01), Andersen et al.
patent: 6114354 (2000-09-01), Andersen et al.
patent: 6153626 (2000-11-01), Pelcman et al.
patent: 7060711 (2006-06-01), Lubbert et al.
patent: 2003/0018447 (2003-01-01), Florschuetz
patent: 2003/0166672 (2003-09-01), Lubbert et al.
patent: 2005/0009860 (2005-01-01), Carson et al.
patent: 2006/0030585 (2006-02-01), Dax et al.
patent: 2006/0135522 (2006-06-01), Carson et al.
patent: 2006/0135524 (2006-06-01), Carson et al.
patent: 2006/0135763 (2006-06-01), Coats et al.
patent: 2006/0148823 (2006-07-01), Coats et al.
patent: 2006/0287297 (2006-12-01), DeCorte et al.
patent: 2009555 (1970-02-01), None
patent: 0005607 (1979-11-01), None
patent: 1049676 (2000-11-01), None
patent: 1306376 (2003-05-01), None
patent: 1321169 (2003-06-01), None
patent: 2290202 (1976-06-01), None
patent: 1128734 (1968-10-01), None
patent: WO 98/28275 (1998-07-01), None
patent: WO 9900376 (1999-01-01), None
patent: WO 0146191 (2001-06-01), None
patent: WO 0166543 (2001-09-01), None
patent: WO 0172303 (2001-10-01), None
patent: WO 02/36573 (2002-05-01), None
patent: WO 02/48122 (2002-06-01), None
patent: WO 03035646 (2003-05-01), None
patent: WO 04026030 (2004-04-01), None
patent: WO 04035540 (2004-04-01), None
patent: WO 04092165 (2004-10-01), None
patent: WO 05003131 (2005-01-01), None
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Prefac & Chapter 8, pp. 279-308.
Commercial 2-Bromo-Phenols from Sigma-Aldrich.
Commercial 4-piperidinones.
Frontier Scientific (Logan, UT) Commercial Boronic Acids.
Hutchins, R.O. et. al. J. Orig. Chem. 1977, 42, 82-91.
Quock et al., “The d-Opioid Receptor: Molecular Pharmacology, Signal Transduction, and the Determination of Drug Efficacy” Pharmacological Reviews 1999, 51(3), 503-532.
Mark Connor and Macdonald J Christie “Opioid Receptor Signaling Mechanisms” Clinical and Experimental Pharmacology and Physiology 1999 26, 493-499.
Terry Kenakin and Ongun Onaran “The ligand paradox between affinity and efficacy: can you be there and not make a difference?” TRENDS in Pharmacological Sciences 2002, 23, 275-280.
Nieschulz, Otto: Hoffmann, Irmgard; Popendiker, Kurt “Pharmacological studies on 10-(I-methyl-3-piperidyl)-2 methoxyphenothiazine and related compounds” Arzneimittel-Forschung 1960, 10, 156-65.
Thomas, J.B. et al ‘(±)-4-[(N-Allyl-CIS-3-Methyl-4-Piperidinyl)Phenylamino]-N,N-Diethylbenzamide Displays Selective binding for the Delta Opioid Receptor’ Bioorganic & Medicinal Chemistry Letters. vol. 9, No. 20 (1999) pp. 3053-3056.
Thomas, J.B. et al ‘Factors Influencing Agonist Potency and Selectivity for the Opioid δ Receptor are Revealed in Structure-Activity Relationship Studies of the 4-[(N-Substituted-4-piperidinyl)arylamino]-N,N-diethylbenzamides’ J. Med. Chem. vol. 44, No. 6 (2001) pp. 972-987.
PCT International Search Report dated Jun. 22, 2006 for PCT Application No. PCT/US2006/000491 dated Jan. 5, 2006 which relates to U.S. Appl. No. 11/326,084 and a Written Opinion dated Jun. 22, 2006.
Kaiser, C. et al., “Analogs of Phenothiazines. 5. Synthesis and Neuropharmacological Activity of Some Piperidylidene Derivatives of Thioxanthenes, Xanthenes, Dibenzoxepins, and Acridans”,J. Med. Chem., 1974, pp. 57-62, vol. 17, No. 1.
Wentland, M. et al., “8-Aminocyclazocine Analogues: Synthesis and Structure-Activity relationships”,Bioorganic&Med. Chem. Lett., 2000, pp. 183-187, vol. 10, No. 2.
Wentland, M. et al., “Selective Protection and Functionalization of Morphine: Synthesis and Opioid Receptor Binding Properties of 3-Amino-3-desoxymorphine Derivatives”,J. Med. Chem.2000, pp. 3558-3565, vol. 43, No. 19.
Wentland, M. et al., “3-Carboxamide Analogues of Morphine and Naltrexone: Synthesis and Opioid Receptor Binding Properties”,Bioorganic&Med. Chem. Lett., 2001, pp. 1717-1721, vol. 11.
Wentland, M. et al., “8-Carboxamidocyclazocine Analogues: Redefining the Structure-Activity Relationships of 2,6-Methano-3-benzazocines”,Bioorganic&Med. Chem. Lett., 2001, pp. 623-626, vol. 11.
Bidlack, J.M., “8-Carboxamidocyclazocine: A Long-Acting, Novel Benzomorphan”,J. Pharm.&Exp. Ther.2002, pp. 374-380, vol. 302, No. 1.
Wentland, M. et al., “Synthesis and Opioid Receptor Binding Affinities of 8-Amino-2,6-methano-3-benzazocines”,J. Med. Chem.2003, pp. 838-849, vol. 46.
Wentland, M. et al., “Redefining the Structure—Activity Relationships of 2,6-Methano-3-benzazocines. Part 2:8-Formamidocylclazocine Analogues”.Bioorganic&Med. Chem. Lett.2003, pp. 1911-1914, vol. 13.
Wentland, M. et al., “Thioformamido and Thiocarboxamido Derivatives of Cyclazocine: Syntheses and Opioid Receptor Bnding Properties”,Abstract of Paper, 226thACS Natl. Mtg., N.Y.2003.
Zhang, A. et. al., “10-Ketomorphinan and 3-Substituted-3-desoxymorphinan Analogues as Mixed κ and μ Opioid Ligands: Synthesis and Biological Evaluation of Their Binding Affinity at Opioid Receptors”,J. Med. Chem., 2004, pp. 165-174, vol. 47, No. 1.
Wentland, M. et al., “Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 3: 8-Thiocarboxamido and 8-thioformamido derivatives of cyclazocine”,Bioorganic&Med. Chem. Lett., 2005. pp. 2547-2551, vol. 15.
Wentland, M. et al., “Synthesis and opioid receptor binding properties of a highly potent 4-hydroxy analogue of naltrexone”,Bioorganic&Med. Chem. Lett., 2005, pp. 2107-2110.
Sun, X., et al. “Synthesis and Opioid Receiptor Binding Properties of Conformation-Rigidified Analogues of 8-Carboxamidocyclazocine and 8-Formamidocyclazocine”,Abstract of Papers, 229thACS Natl. Mtg., N.Y.2005.
VanAlstine, M. A., “Synthesis and evaluation of novel N-substituted derivatives of 8-carboxamidocyclazocine”, Abstract of papers 231stACS National Meeting, Atlanta, GA, 2006, MEDI-009.
Gilbert, P.E. et al.: “The Effects of Morphine- and Nalophine-Like Drugs in the Nondependent, Morphine-Dependent and Cyclazocine-dependent Chronic Spinal Dog1”; The J. of Pharm. And Exp. Thera. (1976) 198(1): 66-82.
Gross, R.A. et al: “dynorphin A and cAMP-dependent protein kinase independently regulate calcium currents”; Proc. Natl. Acad. Sci. (1990) 87: 7025-7029.
Gould, P.L.: “Salt selection for basic drugs”; Intl. J. of Pharm. (1986) 33: 201-217.
Hancock, B.C. et al.: “Characteristics and Significance of the Amorphous State in Phramaceutical Systems”; J. of Pharm. Sciences, (Jan. 1997) 86(1): 1-12.
Kaiser, C. et al.: “Analogs of Phenothiazines. 5. Synthesis and Neuropharmacological Activity of Some Piperidylidene Derivatives of Thioxanthenes, Xanthenes, Dibenzoxepins, and Acridans”; J of Med. Chem. (1974) 17(1): 57-62.
Lord, John A.H. et al.: “Endogenous opioid peptides: multiple agonists and receptors”; Nature (1977) 267: 495-499.
Mansour, A. et al.: “Anatomy of CN
Coats Steve J.
Dax Scott L.
DeCorte Bart
Liu Li
McDonnell Mark
Desai Rita
Janssen Pharmaceutica N.V.
O'Dell David K
LandOfFree
Piperdinyl-phenoxazine and phenothiazine derivatives as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Piperdinyl-phenoxazine and phenothiazine derivatives as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperdinyl-phenoxazine and phenothiazine derivatives as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4004131